Journal of Translational Medicine (May 2022)

Patient-derived xenograft (PDX) models, applications and challenges in cancer research

  • Shahrokh Abdolahi,
  • Zeinab Ghazvinian,
  • Samad Muhammadnejad,
  • Mahshid Saleh,
  • Hamid Asadzadeh Aghdaei,
  • Kaveh Baghaei

DOI
https://doi.org/10.1186/s12967-022-03405-8
Journal volume & issue
Vol. 20, no. 1
pp. 1 – 15

Abstract

Read online

Abstract The establishing of the first cancer models created a new perspective on the identification and evaluation of new anti-cancer therapies in preclinical studies. Patient-derived xenograft models are created by tumor tissue engraftment. These models accurately represent the biology and heterogeneity of different cancers and recapitulate tumor microenvironment. These features have made it a reliable model along with the development of humanized models. Therefore, they are used in many studies, such as the development of anti-cancer drugs, co-clinical trials, personalized medicine, immunotherapy, and PDX biobanks. This review summarizes patient-derived xenograft models development procedures, drug development applications in various cancers, challenges and limitations.

Keywords